Clinical Studies


Promotes Clinical Attachment Gain2

ATRIDOX® is clinically proven to increase clinical attachment when compared to scaling and root planing, oral hygiene or placebo.

The clinical attachment gain after nine months is 0.8 mm.


Reduction in Probing Depth2

When compared to oral hygiene, or placebo, ATRIDOX® reduced probing depth caused by periodontitis. After nine months, ATRIDOX® reduced the probing depth by 1.2 mm.


Reduces Bleeding Upon Probing

ATRIDOX® was more effective than oral hygiene and placebo in reducing gum bleeding upon probing.2, 5

ATRIDOX® maintains sustained reduction of red complex bacteria over six months4

ATRIDOX® significantly reduced two of the most prevalent pathogens associated with periodontal disease, P. gingivalis and T. forsythia.


ATRIDOX® is shown to significantly reduce red complex bacteria in patients who smoke6

At three months, ATRIDOX® plus scaling and root planing substantially reduced P. gingivalis and T. forsythia.

P. gingivalis and T. forsythia combined were reduced by 82 percent compared to 33 percent for scaling and root planing alone.


ATRIDOX® demonstrated a 45 percent reduction in probing depth in smokers with pockets > 7 mm7

Chart compares probing depth reduction at six months after scaling and root planing alone versus ATRIDOX® plus scaling and root planing.